Invokamet Xr Tablet, Film Coated, Extended Release
Product Images NDC 50458-941

14 FDA label images from Janssen Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Invokamet Xr (NDC 50458-941). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Invokamet 01)

Chemical Structure (Invokamet 01)
Chemical structure diagram depicting the active ingredient canagliflozin, as part of the product INVOKAMET, showing its molecular framework including rings, hydroxyl groups, and attached fluorophenyl and thienyl groups, with a notation of half water of hydration (1/2 H2O).*
FDA Label Image

Chemical Structure (Invokamet 02)

Chemical Structure (Invokamet 02)
Chemical structure diagram depicting metformin hydrochloride, a component of the pharmaceutical product INVOKAMET. The structure shows a biguanide group with two methyl substitutions and a hydrochloride ion (HCl).*
FDA Label Image

Figure 1 (Invokamet 03)

Figure 1 (Invokamet 03)
A line graph illustrating the least squares mean change in HbA1c (%) from baseline over 52 weeks, comparing treatment effects of canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride. The x-axis shows study weeks, and the y-axis shows the change in HbA1c. Data points indicate HbA1c reduction trends with standard error bars for each treatment group over time.*
FDA Label Image

Figure 2 (Invokamet 04)

Figure 2 (Invokamet 04)
A line graph comparing the least squares mean change in HbA1c percentage from baseline over a 52-week study period between Canagliflozin 300 mg and Sitagliptin 100 mg. The x-axis represents study weeks, and the y-axis represents LS mean change in HbA1c with standard error bars. Canagliflozin shows a slightly greater and more sustained reduction compared to Sitagliptin over time.*
FDA Label Image

Figure 3 (Invokamet 05)

Figure 3 (Invokamet 05)
A Kaplan-Meier curve comparing percentage of subjects with events over time (weeks) between canagliflozin (dashed line) and placebo (solid line) treatment groups. The graph includes a hazard ratio with 95% confidence interval (HR 0.86, 95% CI 0.75-0.97) and a table below showing the number of subjects at risk at various time points for each group.*
FDA Label Image

Figure 4 (Invokamet 06)

Figure 4 (Invokamet 06)
A Kaplan-Meier survival curve showing the percentage of subjects with events over time (weeks) comparing Cana (canagliflozin) versus Placebo. The Y-axis represents the percentage of subjects with events, and the X-axis represents time in weeks, up to approximately 182 weeks. Two lines illustrate the difference in event rates, with Cana consistently below Placebo. A table below the graph displays the number of subjects at risk at various time points for both groups. The hazard ratio (HR) with 95% confidence interval is noted as 0.70 (0.59, 0.82).*
FDA Label Image

Invokamet 50500 Label (Invokamet 50500 Label)

Invokamet 50500 Label (Invokamet 50500 Label)
Label for Invokamet tablets containing 50 mg canagliflozin and 500 mg metformin hydrochloride. The label states the product contains 60 tablets, is prescription-only, and is manufactured by Janssen Pharmaceuticals, Inc. Storage and dispensing instructions, recommended dosage temperature range, and a barcode are visible.*
FDA Label Image

Invokamet 501000 Label (Invokamet 501000 Label)

Invokamet 501000 Label (Invokamet 501000 Label)
Label for Invokamet tablets containing canagliflozin and metformin hydrochloride, with a strength of 50 mg/1,000 mg. The package contains 60 film-coated tablets. Manufactured by Janssen Pharmaceuticals, Inc., licensed from Mitsubishi Tanabe Pharma Corporation, and distributed by Johnson & Johnson. The label includes storage instructions and prescription-only status.*
FDA Label Image

Invokamet 150500 Label (Invokamet 150500 Label)

Invokamet 150500 Label (Invokamet 150500 Label)
Label for INVOKAMET tablets containing 150 mg canagliflozin and 500 mg metformin hydrochloride. The film-coated oral tablets are labeled by Janssen Pharmaceuticals, Inc. The package contains 60 tablets with NDC 50458-542-60. The label includes instructions to dispense the enclosed medication guide and store the medication properly, along with manufacturer and licensing information.*
FDA Label Image

Invokamet 1501000 Label (Invokamet 1501000 Label)

Invokamet 1501000 Label (Invokamet 1501000 Label)
Invokamet 150 mg / 1,000 mg tablets label for oral use. Contains canagliflozin and metformin hydrochloride. The package holds 60 film-coated tablets. Manufactured for Janssen Pharmaceuticals, Inc., licensed from Mitsubishi Tanabe Pharma Corporation. Label includes storage instructions and dosage information, with Johnson & Johnson branding.*
FDA Label Image

Invokamet Xr 50500 Label (Invokamet Xr 50500 Label)

Invokamet Xr 50500 Label (Invokamet Xr 50500 Label)
Invokamet XR 50 mg/500 mg extended-release tablets, film-coated oral tablets containing canagliflozin and metformin hydrochloride. The label indicates the package contains 60 tablets and is labeled for prescription use only by Janssen Pharmaceuticals, Inc. Storage instructions and dispensing warnings are also included.*
FDA Label Image

Invokamet Xr 501000 Label (Invokamet Xr 501000 Label)

Invokamet Xr 501000 Label (Invokamet Xr 501000 Label)
Packaging label for INVOKAMET XR extended-release tablets containing canagliflozin and metformin hydrochloride. The label states the strength as 50 mg of canagliflozin and 1,000 mg of metformin per tablet. The package contains 60 tablets. Manufacturer is Johnson & Johnson, with Janssen Pharmaceuticals, Inc. as the labeler.*
FDA Label Image

Invokamet Xr 150500 Label (Invokamet Xr 150500 Label)

Invokamet Xr 150500 Label (Invokamet Xr 150500 Label)
Label for Invokamet XR extended-release tablets, containing 150 mg canagliflozin and 500 mg metformin hydrochloride. The package contains 60 film-coated tablets. It includes dosage form, strength, and manufacturer Johnson & Johnson with storage and dispensing instructions.*
FDA Label Image

Invokamet Xr 1501000 Label (Invokamet Xr 1501000 Label)

Invokamet Xr 1501000 Label (Invokamet Xr 1501000 Label)
Invokamet XR 150 mg/1,000 mg extended-release tablets, containing canagliflozin and metformin hydrochloride, presented in a 60-tablet package. The label shows the Johnson & Johnson logo and includes storage instructions and dispensing guidance. It is manufactured for Janssen Pharmaceuticals, Inc., licensed from Mitsubishi Tanabe Pharma Corporation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.